NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/04/2026
Voltar para busca
Dado oficial do USPTO
QUIAPEG PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
24/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42
Data de depósito
02/09/2019
Data de registro
27/09/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/09/2022
Última transação
24/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
SE
Examinador
CROWLEY, SEAN MICHAEL
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "QUIAPEG" in blue and "PHARMACEUTICALS" in orange and the design a blue hexagon containing three diagonal blue lines with a wavy orange line emanating from its center. The white in the drawing represents background and is not part of the mark.
Titulares e representantes
Titulares
QuiaPEG Pharmaceuticals AB
Representantes
Cynthia Johnson Walden Fish & Richardson P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Regents for use in industry and sciencereagents for use with a drug delivery system comprising phosphotriester linkers for the controlled release of a wide variety of therapeutic agents; cross linking agents being industrial chemicals for use in industry and science; polyethylene glycols for use in industry and science; chemical structures being industrial chemicalsphosphotriester linkers
Classe 5
Pharmaceuticalsmedical and veterinary preparations for the treatment of cancercardiovascular diseaserespiratory disordersmetabolic disordersautoimmune diseaseneurologic and psychiatric disorders and infectious disease derived from PEGylation technologies; pharmaceutical preparationsa drug delivery system comprising phosphotriester linkers for the controlled release of a wide variety of therapeutic agents; pharmaceuticalmedical and veterinary substances
Classe 42
Scientific and technological servicesscientific researchanalysistesting and development in the field of pharmaceuticalsof pharmaceuticalmedical and veterinary preparations and substances derived from PEGylation technologies; PEGylation pharmaceuticals research services
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/02/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/01/2023
FIMP
FINAL DISPOSITION PROCESSED
18/01/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/12/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
27/09/2022
GPNX
NOTIFICATION PROCESSED BY IB
12/07/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/07/2022
PUBO
PUBLISHED FOR OPPOSITION
12/07/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/06/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/06/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/06/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/06/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
03/06/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/06/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
03/06/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/06/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/04/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
21/04/2021
ATRV
ATTORNEY REVIEW COMPLETED
01/09/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/08/2020
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
04/08/2020
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
17/07/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
14/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/07/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
01/07/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/07/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
01/07/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/05/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/05/2020
ALIE
ASSIGNED TO LIE
28/05/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/05/2020
RFNT
REFUSAL PROCESSED BY IB
07/03/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/02/2020
RFRR
REFUSAL PROCESSED BY MPU
14/02/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/01/2020
CNRT
NON-FINAL ACTION WRITTEN
21/01/2020
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
05/12/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/12/2019
CNRT
NON-FINAL ACTION WRITTEN
04/12/2019
DOCK
ASSIGNED TO EXAMINER
04/12/2019
MAFR
APPLICATION FILING RECEIPT MAILED
29/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/11/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QUIAPEG PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.